Description
Atenativ (Antithrombin i) 500 IU Antithrombus i №1 Vial + Solvent 10 ml
Composition
Active Ingredient: Antithrombin i 500 IU
Mechanism of Action
Antithrombin i functions as a natural anticoagulant by inhibiting thrombin and other coagulation factors, thereby regulating the coagulation cascade and preventing excessive blood clot formation.
Pharmacological Properties
Atenativ, with antithrombin i as the active component, exhibits anticoagulant properties through the inhibition of coagulation factors, ultimately reducing the risk of thromboembolic events in patients with antithrombin deficiency.
Indications for Use
Indications: Atenativ is indicated for the prevention of thromboembolic events in patients diagnosed with hereditary antithrombin deficiency.
Contraindications
Contraindications: Atenativ is contraindicated in individuals with a known hypersensitivity to antithrombin products.
Side Effects
Common side effects of Atenativ may include allergic reactions, injection site reactions, or rare cases of bleeding disorders. Patients should consult their healthcare provider for a complete list of potential adverse effects.
Usage Instructions
Administration: Atenativ is administered intravenously under the close supervision of a qualified healthcare professional. The dosage and frequency of administration should be determined by the treating physician based on individual patient characteristics.
Benefits Compared to Analogues
Atenativ offers a targeted approach to preventing thromboembolic events specifically in patients with hereditary antithrombin deficiency, providing a specialized treatment option with proven efficacy and safety profile compared to general anticoagulant therapies.
Suitable Patient Groups
Atenativ is suitable for use in adult patients with hereditary antithrombin deficiency who require anticoagulant therapy. The dosage and administration in pediatric or elderly patients should be determined by a healthcare professional based on individual needs and considerations.
Storage and Shelf Life
It is recommended to store Atenativ as per the instructions provided on the packaging. Ensure proper storage conditions to maintain the integrity and efficacy of the product. Check the expiration date on the packaging and do not use the product beyond the stated shelf life.
Packaging Description
Atenativ is available in vial form, containing 500 IU of antithrombin i, along with a 10 ml solvent for reconstitution. The packaging should include clear instructions for preparation and administration.
Clinical Evidence and Proven Effectiveness
Atenativ, with antithrombin i as the key component, has demonstrated efficacy in preventing thromboembolic events in patients with antithrombin deficiency. Research published in the Journal of Thrombosis and Haemostasis has emphasized the role of antithrombin supplementation in reducing thrombotic events in high-risk patient populations.
Clinical studies have shown that Atenativ is well-tolerated and effective in reducing the risk of thromboembolic events when used as directed by healthcare professionals.
